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Lichenicidin is a class II two-component lantibiotic
produced by Bacillus licheniformis. It is composed
of the two peptides Blia and Blib, which act synergis-
tically against various Gram-positive bacteria. The
lichenicidin gene cluster was successfully expressed
in Escherichia coli, thus constituting the first report to
our knowledge of a full reconstitution of a lantibiotic
biosynthetic pathway in vivo by a Gram-negative
host. This system was further exploited to charac-
terize and assign the function of proteins encoded
in the biosynthetic gene cluster in the maturation of
lichenicidin peptides. Moreover, a trans complemen-
tation system was developed for expression of Blia
and Blib variants in vivo. This contribution will spur
future studies in the heterologous expression and
engineering of lantibiotics.
INTRODUCTION
Bacillus licheniformis is a Gram-positive endospore-forming
microorganism commonly found in soil, which belongs to the
B. subtilis group. Members of this genus have been described
as producers of biotechnologically important compounds such
as proteases, amylases, antibiotics, and surfactants. The
produced antimicrobial compounds include predominantly
peptides that are either nonribosomally or ribosomally synthe-
sized (Stein, 2005).
Lantibiotics are ribosomally synthesized as inactive prepepti-
des which are posttranslationally modified to their biologically
active forms (Chatterjee et al., 2005). The common structural
feature of lantibiotics is the unusual amino acids lanthionine
(Lan) and/or methyllanthionine (MeLan). Specific Ser and Thr
residues are the precursors to enzymatic dehydration to yield
2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb),
respectively. Subsequently, Dha and Dhb form a thioether with
thiol side chains of Cys via a Michael addition-type to yield Lan
and MeLan, respectively (Willey and van der Donk, 2007). These
posttranslational modifications occur in the C-terminal region of
the prepeptide, while the unmodified N-terminal region (leader90 Chemistry & Biology 18, 90–100, January 28, 2011 ª2011 Elseviersequence) is proteolytically removed to yield the active lantibi-
otic (Chatterjee et al., 2005).
Lantibiotics can be classified based on their maturation
pathway and antimicrobial activity (Pag and Sahl, 2002; Willey
and van der Donk, 2007). The release of B. licheniformis
DSM13 (isogenic to ATCC 14760) genome (Rey et al., 2004; Veith
et al., 2004) in 2004 allowed the identification of a putative
lantibiotic gene cluster, which was recently associated with the
lichenicidin production (Begley et al., 2009; Dischinger et al.,
2009). According to a previously suggested classification (Willey
and van der Donk, 2007), lichenicidin is a two-component
lantibiotic, a subgroup of antibacterial class II lantibiotics. In
two-component lantibiotics, two different structural genes
(lanA1 and lanA2) are expressed and subsequently modified by
two different LanM proteins (LanM1 and LanM2). After post-
translational modification both peptides are exported and their
leader sequences removed by a single, multifunctional protein
possessing an N-terminal protease domain designated LanT.
Some of these compounds might undergo an additional
N-terminal proteolytic step presumably by the action of an extra-
cellular protease.
Generally, a- and b-peptides of two-component lantibiotics
act synergistically to exert their full antibacterial activity. Pres-
ently, this group includes eight lantibiotics including haloduracin
and lacticin 3147 (Figure 1) (Lawton et al., 2007; McClerren et al.,
2006; Ryan et al., 1996).
The lichenicidin complex is active against methicillin-resistant
Staphylococcus aureus (MRSA) and Listeria monocytogenes
(Begley et al., 2009; Dischinger et al., 2009). It is believed that
two-component lantibiotics mechanism of action involves the
interaction of both peptides through the binding to lipid II and
formation of pores in the bacterial membrane (Oman and van
der Donk, 2009; Schneider and Sahl, 2010).
Apart from their antibacterial activity, other interesting bioac-
tivities have recently been described for lantibiotics, e.g., type
III lantibiotics possess antipain activity in a mouse model of
neuropathic pain (Meindl et al., 2010). Consequently, during
the last years, the evaluation of lantibiotic structure-activity rela-
tionships has increased, since the information retrieved can be
further used in the rational design of new molecules with
improved activity (Cortes et al., 2009). Such studies, using site-
directed mutagenesis, have already been conducted in vivo for
lacticin 3147 peptides (Cotter et al., 2006) and in vitro for halo-
duracin (Cooper et al., 2008). This approach was also usefulLtd All rights reserved
Figure 1. Structure of Class II Lantibiotics
Proposed structures of Blia and Blib peptides of the lichenicidin complex (A) and of the related lantibiotics haloduracin, lacticin 3147 and mersacidin (B).
Nondehydrated residues are represented in green and the highly conserved Glu residue in purple (Ala-S-Ala = lanthionine, Abu-S-Ala = methyllanthionine and
OBu = 2-oxobutyryl). See also Figures S2–S4.
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b-peptide (Cooper et al., 2008). Moreover, a saturationmutagen-
esis library of mersacidin was recently constructed yielding
the production of 82 new compounds in which some of them
demonstrated improved activity against Gram-positive patho-
gens (Appleyard et al., 2009).
Herein, we report the first heterologous expression of a type-II
two-component lantibiotic gene cluster in E. coli at the example
of lichenicidin from B. licheniformis I89 (Mendo et al., 2000).
Apart from immunity and regulation associated genes the
functions of predicted open reading frames in the cluster were
assigned. Finally, in E. coli a trans complementation system
was established and new lichenicidin variants were generated,
which allowed the assignment of essential residues for expres-
sion and antibiotic activity as well as the characterization ofChemistry & Biology 18, 9structural features previously proposed (Begley et al., 2009).
This is the first report to our knowledge on lantibiotic production
in Gram-negatives, opening new perspectives for the biotechno-
logical studies of these compounds.
RESULTS
Synthesis of the Two-Component Lantibiotics
Blia and Blib by Bacillus licheniformis I89
B. licheniformis I89 was previously described as the producer
of an antibacterial peptide with a molecular mass of 3249.7 Da
(calculated M = 3248.58 Da) (Mendo et al., 2004). In the present
study, another antibacterial peptide with the molecular mass of
3019.6 Da (calculated M = 3018.38 Da) was also identified in
the extracts of this strain. Both peptides were detected by0–100, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 91
Figure 2. ESI-TOF Mass Spectra of Lichenicidin Peptides
ESI-TOF mass spectra of Blia (M = 3249.54 Da) and Blib (M = 3019.38 Da) peptides detected from B. licheniformis I89 supernatant (A) and cell wall washes (B)
extracts. licA1 and licA2 gene inactivation mutants in Lic5DA1 and Lic5DA2 resulted in the production of only Blib (C) and Blia (D), respectively.
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extracts from cultures grown at 37C (Figure 2) and 50C. In
theB. licheniformis ATCC 14760 genome a putative two-compo-
nent lantibiotic gene cluster was identified (Rey et al., 2004). The
products of the structural genes licA1 and licA2 matched with
the abovementioned molecular masses assuming 7 and 12
dehydration reactions of both propeptides. Recently, Begley
et al. (2009) and Dischinger et al. (2009) reported that lichenicidin
peptides (Blia and Blib) production is encoded in this cluster.
We propose that the antibacterial peptides isolated from
B. licheniformis I89 are also lichenicidin and therefore the lichen-
icidin nomenclature will always be adopted.
The analysis of B. licheniformis I89 extracts also revealed the
presence of at least two additional molecules with molecular
masses corresponding to variously dehydrated Blib peptides
(Figure 2).
Heterologous Expression of Lichenicidin
in Escherichia coli
B. licheniformis I89 exhibited low transformation efficiencies,
probably due to class I restriction modification systems previ-
ously identified in B. licheniformis DSM13 (Rey et al., 2004; Veith
et al., 2004). This is a severe impediment for the molecular
biology procedures necessary for gene function analysis and
also for rapid access to mutant strains. Thus, heterologous
expression of lichenicidin was attempted in the Gram-negative
host Escherichia coli. To access the complete gene cluster in
a vector, a fosmid library of B. licheniformis I89 genomic DNA
was constructed in E. coli EPI300 and screened with a DIG-
labeled DNA probe encoding the lichenicidin structural genes
licA1 and licA2. Five positive clones (Lic5, Lic7, Lic8, Lic10,
and Lic45) were identified, containing the lic gene cluster92 Chemistry & Biology 18, 90–100, January 28, 2011 ª2011 Elsevier(approximately 14 Kb) (Figure 3A). All the clones inhibited the
growth of M. luteus and therefore one clone (Lic5) containing
the fosmid pLic5 (Figure 3B) was selected as lichenicidin heter-
ologous expression system. Lichenicidin production by Lic5 was
evaluated along 36 hr in liquid cultures. LC-ESI-MS analysis of
both cell isopropanol washes and supernatant extracts after
24 hr of growth revealed the presence of peptides with molecular
masses corresponding to Blia and Blib. The exciting observation
of successful heterologous expression of the lic cluster in
a Gram-negative organism required closer consideration and
experimental proof. Hence, detection of Blia and Blib observed
in E. coli supernatants could either be explained by bacterial lysis
of the producing strain or by active export through the outer
membrane. Since growth behavior of E. coli carrying the lic
gene cluster was not conspicuous the latter hypothesis was
investigated, analyzing the influence of TolC, an outermembrane
protein commonly involved in the export of toxins on lichenicidin
production. Therefore, E. coli BW25113 possessing a deletion of
the tolC genewas transformedwith the fosmid pLic5 carrying the
lic cluster. The resulting E. coli BW25113DtolC:kan-pLic5 strain
did not show antibacterial activity against the indicator strain
M. luteus (see Figure S6 available online) and the molecular
masses of Blia and Blib were not detected by ESI-LC-MS anal-
ysis of supernatant extracts. Trans complementation of this
strain with tolC resulted in restoration of antibacterial activity
(Figure S6). This was further corroborated by detection of char-
acteristic masses of Blia and Blib by means of HPLC-ESI-MS
from supernatant extracts (data not shown).
Mutagenesis of the Lichenicidin Biosynthetic Cluster
The lic biosynthetic gene cluster (Figure 3A) is composed of 14
open reading frames (ORFs). Expression of these genes inLtd All rights reserved
Figure 3. Lichenicidin Gene Cluster and pLic5 Map
(A) Organization of the lichenicidin biosynthetic gene cluster, according to the genome annotation forBacillus licheniformisATCC14760. Black circles correspond
to deduced Rho-dependent terminators.
(B) Representation of the pLic5 fosmid map, containing the lichenicidin biosynthetic gene cluster.
See also Table S1.
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vated mutants using the l RED recombinase system (Datsenko
and Wanner, 2000; Gust et al., 2003). To that end, the fosmid
pLic5 was introduced into BW25113 cells containing the RED
recombinase expression plasmid pKD20 (Datsenko and
Wanner, 2000). The transformed strain was used as a platform
for the inactivation of all ORFs of the lic cluster, except those
presumably associated with self-immunity. In total, nine fosmids
were constructed, each of them containing the deletion of one
gene in BW25113 cells and transformed into EPI300 cells (Table
S1). Overall, the expression of eight ORFs was found to be
critical for lichenicidin production (Figure 4A). Only the Lic5DX
knockout mutant retained visible antibacterial activity against
the indicator strain M. luteus (Figure 4A).
According to previous studies on two-component lantibiotics,
it was expected that the single production of either Blia or Blib
would result in significantly reduced antibacterial activity.
Consequently, the loss of activity by mutational inactivation of
lic genes could result from the absence of production of both
or only one of the lichenicidin peptides. If the second assumption
was correct, antibacterial activity should be restored if the
complementing peptide could be externally supplied by cross-
feeding. Indeed, this was observed when the two strains missing
the respective intact structural genes (Lic5DA1 and Lic5DA2)
were bioassayed as neighboring colonies (Figure 4B). Moreover,
noM. luteus inhibition was observed when Lic5DA1mutant was
inoculated next to Lic5DA1, or Lic5DA2 next to Lic5DA2.
LC-ESI-MS analysis of both clones revealed that Lic5DA1
synthesized exclusively the Blib peptide and Lic5DA2 synthe-
sized exclusively the Blia peptide (Figures 2C and 2D). These
results showed that inhibition of M. luteus was a consequence
of the synergistic activity of both peptides. Therefore, Lic5DA1
and Lic5DA2 were used in cross-feeding agar-diffusion assays
with the other knockout mutants. Full restoration of antibacterialChemistry & Biology 18, 9activity was observed between the following combinations of
knockout mutant pairs: Lic5DA1 with Lic5DM2, Lic5DP and
Lic5DR; Lic5DA2 with Lic5DM1 and Lic5DY (Figure 4C). These
results were predictive of peptide production in each knockout
mutant and were unambiguously confirmed by LC-ESI-MS
analysis (Table S1).
LC-ESI-MS analysis of the mutants obtained from inactivation
of dehydratase-cyclases Lic5DM1 and Lic5DM2, showed the
same results as those obtained with the mutants of the structural
genes Lic5DA1 and Lic5DA2, respectively. Molecular masses
corresponding to propeptides or prepropeptides were not
detected.
Sequence homology studies identified LicT from the
B. licheniformis I89 lic cluster as a member of the ABC trans-
porter family with an integrated protease domain, presumably
responsible for removal of the leader sequences of Blia and
Blib during substrate translocation. In E. coli, the inactivation of
licT (Lic5DT) resulted in the loss of visible antibacterial activity,
which was not restored by interaction with Lic5DA1 or Lic5DA2.
Accordingly, molecular masses of Blia and Blib peptides were
not identified in the Lic5DT supernatant extracts by LC-ESI-
MS. However, when isopropanol washes of Lic5DT cells were
analyzed by LC-ESI-MS a peptide mass corresponding to fully
processed Blibwas identified, albeit in extremely low concentra-
tion. It is likely that isopropanol treatment of Lic5DT cells
released Blib propetide to interact with the protease LicP (active
in this mutant), thus yielding correctly processed Blib peptide
without the leader sequence.
The licX gene encodes a small uncharacterized hypothetical
protein with significant homology to other uncharacterized
Bacillus sp. proteins. The absence of conserved core motifs in
this protein makes it difficult to predict its function. When licX
was inactivated, the antibacterial activity of Lic5DX was not
affected and both peptides Blia and Blib were identified in0–100, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 93
Figure 4. Bioactivity of Knockout Mutants
Agar diffusion assay to assess lichenicidin production by the knockout
mutants of the lic gene cluster using M. luteus as the indicator strain. Lic5
gene inactivation mutants are represented by DA1, DA2, DM1, DM2, DT,
DP, DX, DR and DY, according with the inactivated gene. (A) Antibacterial
activity exhibited by all knockout mutants produced in this study. (B) Syner-
getic activity of peptides Blia and Blib, produced by Lic5DA2 and Lic5DA1,
respectively. (C) Restored lichenicidin activity of the knockout mutants upon
interaction with Blib and Blia peptides produced by Lic5DA1 and Lic5DA2,
respectively. See also Figure S1.
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tial role in lichenicidin production.
Downstream of licX, two other genes, licR and licY, were
identified. NCBI Conserved Domain Searches of the licR
sequence revealed a high homology to helix-turn-helix XRE
family-like proteins. After its deletion only Blib was identified by
LC-ESI-MS analysis of Lic5DR extracts. This result demon-
strates that LicR might have an essential regulatory function in
the biosynthesis of mature LicA2 peptide. Finally, the Lic5DY
mutant was identified as the only producer of the Blia peptide.
This proved an essential involvement of LicY in the biosynthesis
of Blib but not in the biosynthesis of Blia. Three transmembrane
helices identified in LicY point to a likely role as a membrane
protein.LicP, A Protease Involved in Blib Biosynthesis
Blia and Blib prepropeptides both have a common proteolytic
site for LicT (C-terminal of the Gly-Gly-motif). The molecular
mass of the processed Blib peptide affords additional proteol-
ysis of an N-terminal hexapeptide of the Blib’ peptide (corre-
sponding to H2N-NDVNPE-Blib). Such second proteolysis step
has been described for other two-component lantibiotics, e.g.,
Halb, Plwb, CylLL, and CylLS (Booth et al., 1996; Holo et al.,
2001;McClerren et al., 2006). In the lic gene cluster, licP encodes
a putative uncharacterized serine protease homologous to
CylA (38% identity) from Enterococcus faecalis (CylLL and
CylLS producer) and to BH1491 uncharacterized protease
(30% identity) from B. halodurans C-125 (Halb producer).94 Chemistry & Biology 18, 90–100, January 28, 2011 ª2011 ElsevierTherefore, it was considered that LicP could be the protease
postoperative to LicT responsible for the removal of the hexa-
peptide NDVNPE from Blib’. In fact, when licP was deleted
only the production of Blib was negatively affected. The E. coli
Lic5DP mutant lost antibacterial activity, which could be
restored upon cross feeding with a mutant delivering correctly
processed Blib peptide e.g., mutant Lic5DA1 (Figure 4C). Hence,
in Lic5DP isopropanol washes of cells and supernatant extracts
only the molecular mass of the Blia was identified. Molecular
masses corresponding to the N-terminally untrimmed Blib
peptide (calculated M = 3686.65 Da) or those of its derivatives
could not be identified. However, when E. coli Lic5DP cell and
supernatant extracts where bioassayed next to filter-sterilized
supernatants of an E. coli strain solely expressing LicP (BL21
licP+), the reestablishment of antibacterial activity was observed
(Figure S1). This indicated that fully active Blib was produced
in situ and could act synergistically with the Blia peptide.
A Complementation System for Expression
of Lichenicidin Peptide Derivatives in E. coli
The construction of a system enabling generation of lichenicidin
variants was developed, due to its usefulness for both structure-
activity relationship (SAR) analysis and structure elucidation
purposes. To that end, E. coli BL21Gold producing exclusively
one of the prepeptides were obtained by transformation of these
cells with pLic5DA1 or pLic5DA2 fosmids, generating BLic5DA1
and BLic5DA2 strains, respectively. These strains were comple-
mented with the respective deleted genes (licA1 and licA2)
cloned into the expression vector pET-24a(+). The resulting
transformants BLic5DA1+ (BLic5DA1+plicA1) and BLic5DA2+
(BLic5DA2+plicA2) were able to inhibit the indicator strain and
the molecular masses of both Blia and Blib by LC-ESI-MS
were successfully identified. Therefore, this system was further
exploited by PCR site-directedmutagenesis of plicA1 and plicA2
in order to obtain E. coli strains producing Blia and Blib variants.
During this procedure, only one of the lichenicidin peptides was
mutated at each time, facilitating an exact assignment of the
impact of the introduced alteration also in production and/or
bioactivity. The generation of 32 lichenicidin variants was at-
tempted, which molecular masses are summarized in the
supplementary information (Table S2).
In this study a systematic Ala scan was performed for all Cys,
Ser, and Thr residues of Blia and Blib. Especially C-terminal
substitutions of residues BliaThr24, BlibThr25, BlibCys28, and
BlibThr29A did not yield the corresponding mutant peptide
(HPLC-ESI-MS control) and consequently no bioactivity was
observed (Figure 5). All other lichenicidin variants were synthe-
sized although to a different extent. Some of the peptides
variants were produced in low amounts and therefore were not
used in bioactivity assays (Figure 5). Peptides which were
produced in amounts comparable to the wild-type (HPLC-ESI-
MS control) were correlated to bioactivity in agar diffusion tests.
Overall, the changes introduced at theN terminus of Blia andBlib
seem to be less prejudicial for lichenicidin bioactivity and/or for
peptide production than those at the C terminus (Figure 5).
Homology studies of mersacidin-like two-component lantibi-
otics revealed the presence of a highly conserved glutamate
(Glu17) (Figure 1). Its substitution in mersacidin, Hala and Ltca
completely abolished antibacterial activity (Appleyard et al.,Ltd All rights reserved
Figure 5. Lichenicidin Alanine-Scan Mutagenesis
Supernatant extracts activity (AU.ml-1) of Blia (A) and Blib (B) alanine-scan mutants against M. luteus. Control strains represent the mutants BLicDA1 and
BLicDA2, complemented with plicA1 (A) and plicA2 (B). The primary amino acid sequence and thioether rings of Blia and Blib are represented underneath
the bioactivity results, accordingly with the results obtained in this study (OBu = 2-oxobutyryl). Nonproducer (NP) strains or low-producer (ND) strains of mutated
peptides were not integrated in the bioassay. See also Table S2.
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was proved that Glu17 is essential for binding to the lipid II target
(Brotz et al., 1998; Hsu et al., 2003; Szekat et al., 2003). In the
case of lichenicidin Blia, the substitution of homologous Glu26
by Ala yielded the expected peptide (M = 3191.54 Da), however
antibacterial activity of BliaE26A was completely abolished.
Localization of the N-Terminal Lanthionine
Bridges of Blia and Blib
The determined exact molecular masses of Blia and Blib
peptides (M = 3249.54 Da andM= 3019.6 Da, respectively) differ
from the calculated masses by +1 Da, suggesting that a 2-oxo-
butyryl residue could be present at the N terminus of both
peptides. This hypothesis was also supported by mutant
peptides of Blia and Blib possessing an N-terminal Thr/Ala
replacement thus retaining a conventional N terminus (BliaT1A:
M = 3236.52 Da and BlibT1A: M = 3006.36 Da) and bioactivity.
Hence, establishment of N-terminal A-rings of Blia and Blib
between Dhb1 and Cys7 (Blia) and Dhb1 and Cys11 (Blib)
seemed less likely, contrary to data previously proposed by
Begley et al. (2009). MS/MS analysis of the Blia peptide from
B. licheniformis I89 (Figure 6) and E. coli BLic5 (Figure S3) super-
natants showed the presence of the N-terminal ions a3 and b3,
excluding the possibility of A-ring formation between Cys7 and
Dhb1 or Dhb3. Instead, either Dha5 or Dhb6 were candidates
for A-ring formation with Cys7. This question was further investi-
gated by MS/MS experiments of Blia peptides containing an
Ala5 (BliaS5A mutant) or Thr6 (BliaT6A mutant). The identifica-
tion of the y26 ion for BliaS5A but not for BliaT6A supports
a Blia structure with an A-ring between Dha5 and Cys7 (Fig-
ure 1A; Figure S4). The MS/MS spectra of the Blib peptide
from B. licheniformis I89 (Figure 6) and E. coli BLic5 (Figure S3)
supernatant permitted the identification of a series of fragment
ions (a2, b2, a3, b3, b5, b6, y27, and y26), suggesting that only
Dha7 or Dhb8 were likely to be involved in A-ring formationChemistry & Biology 18, 9with Cys11. The analysis of the bioactivity of the peptides pos-
sessing an Ala residue instead of Dhb2, Dhb5, Dhb6, Dha7,
and Dha8 suggests that Dha7 should be the residue reacting
with Cys11 of Blib peptide (Figures 1A and 5).
Localization of Didehydro Amino Acids in the Structures
of Blia and Blib Peptides
The found molecular masses of Blia and Blib peptides are
consistent with the posttranslational dehydration of seven and
twelve Ser/Thr residues, respectively. Therefore, one and three
Ser/Thr should escape the action of the dehydratase-cyclases
LicM1 and LicM2, respectively. These residues were proposed
to be Ser30 of Blia and Ser21, Thr26 and Ser30 of Blib (Begley
et al., 2009). To confirm this assumption experimentally, these
four residues were mutated to Ala. Analysis of the BliaS30A
mutant revealed the presence of a 7-fold dehydrated peptide
(M = 3233.58 Da). Therefore, Ser30 from Blia escapes dehydra-
tation. The same analysis for Blib mutants BlibS21A and
BlibS30A revealed products withmolecular masses correspond-
ing to the expected twelve dehydratations (M = 3003.40 Da).
Therefore, LicM2 does not modify Ser21 and Ser30. However,
the peptide produced by BlibT26A mutant (M = 3007.40 Da)
was consistent with the occurrence of only eleven, instead of
the proposed twelve dehydratations (calculated M = 2989.37
Da) (Begley et al., 2009). The substitution of Thr10/Ala resulted
in the synthesis of a 12-fold dehydrated peptide (M = 2989.72
Da) (Figure S2 and Table S2). Thus, Thr10 is the candidate amino
acid escaping LicM2 dehydration and this finding was also
included in the Blib structure (Figure 1A).
DISCUSSION
In the light of recent developments in the field of lantibiotic
biosynthesis, the role of lantibiotics for use as antimicrobials is
promissory. This is supported by observations that when0–100, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 95
Figure 6. Blia and Blib ESI-MS/MS Spectra
ESI-MS/MS spectra of Blia (A) and Blib (B) purified from theB. licheniformis I89 supernatant and assigned fragmentation pattern of lichenicidin peptides. See also
Figure S4.
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ment of resistance is believed to be extremely low. Lichenicidin
is a two-component lantibiotic (Blia and Blib) produced by
B. licheniformis. Recently, two independent studies assigned
its production to a biosynthetic gene cluster encoded in
B. licheniformis ATCC 14760 and DSM13 (Begley et al., 2009;
Dischinger et al., 2009). Although not recognized at that time,
Blia production was also reported by Mendo and co-workers96 Chemistry & Biology 18, 90–100, January 28, 2011 ª2011 Elsevierin B. licheniformis I89 supernatant extracts (Mendo et al.,
2004). Herein, lichenicidin peptides Blia and Blib were detected
in cell washes and supernatant extracts of this strain. Thus, in the
I89 strain this lantibiotic is not exclusively cell wall-associated as
it has been described for other strains of this specie (Begley
et al., 2009; Dischinger et al., 2009).
B. licheniformis I89 was not amenable to transformation and
therefore heterologous expression of lichenicidin was attemptedLtd All rights reserved
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Heterologous Expression of Lantibiotics in E. coliin E. coli. This Gram-negative organism is a preferred heterolo-
gous expression host with respect to genetic manipulation,
handling cost and time considerations. The presence of the fos-
mid pLic5 harboring the complete lichenicidin gene cluster in
E. coli (Lic5) resulted in a strain able to inhibit M. luteus growth.
Characteristic molecular masses of fully modified Blia and Blib
peptides were detected by LC-ESI-MS in E. coli Lic5 cell washes
(isopropanol) and supernatant extracts. In the past, the heterol-
ogous production of lantibiotics in E. coli hosts was unknown.
Recently, first steps into this direction where undertaken by the
co-expression of prepeptide and the corresponding modifying
enzyme in E. coli, which achieved establishment of the fully de-
hydrated lantibiotic BovHJ50 (Lin et al., 2010). However, its bio-
logically active form was only obtained after in vitro incubation
with a specific protease (BovT150) to remove the leader
sequence. In contrast, herein we obtained a full reconstitution
of the in vivo synthesis of a lantibiotic in a Gram-negative host.
Moreover, heterologous expression of the lic cluster in a tolC-
deficient E. coli strain revealed the absence of Blia and Blib
peptides in supernatant extracts. This supported the assumption
that TolC and/or TolC-related proteins are likely candidates for
the transport of Blia and Blib through the outer membrane, which
was further corroborated by restoration of lichenicidin activity
upon tolC trans-complementation.
The lichenicidin gene cluster consists of 14 ORFs and in
the past, only the expression of licM1 and licM2 genes was
associated with lichenicidin production (Dischinger et al.,
2009). Therefore, lRED recombinase technology was employed
to inactivate all lic genes in the pLic5 fosmid, except those
putatively related with immunity. Our results showed that licA1
and licA2 encode the lichenicidin prepeptides, which are
posttranslationally modified by bifunctional dehhydratases-
cyclases LicM1 and LicM2, respectively. In the absence of
LicT (E. coli Lic5DT), it was not possible to detect the fully
processed Blia and Blib peptides in supernatant extracts,
indicating that LicT protein plays an essential role in the matura-
tion of both peptides. LicT protein is a member of the ABC
transporter family with an integrated protease domain, appar-
ently responsible for the removal of the leader sequences of
Blia and Blib during their transport. E. coli proteases and toxins
are often exported directly from the cytoplasm to the superna-
tant by a sec-independent type I secretion system (T1S). T1S
affords the presence of an ABC transporter, a membrane fusion
protein (MFP) and an outer membrane protein (OMP; e.g., TolC)
(Kostakioti et al., 2005). Considering this system, it could be
hypothesized that LicT located in the inner membrane is able
to closely interact with MFP and TolC (or TolC-related protein)
of E. coli, forming a T1S-complex responsible for leader peptide
removal and export of Blia and Blib. It is also conceivable,
that LicT removes the leader peptides and transports Blia and
Blib to the periplasmatic space followed by TolC-mediated
export without any interaction between LicT and TolC. Alterna-
tively, Blia and Blib could be exported by inner and outer
membrane transporters provided by the E. coli host. Then
LicT would only contribute a proteolytic function required for
leader peptide removal. Nevertheless, these hypotheses
have to be further evaluated experimentally in order to establish
a comprehensive model for lantibiotics secretion in Gram-nega-
tive hosts.Chemistry & Biology 18, 9LicP is a serine protease homologous to the extracellular
protease CylA (38% identity) which is responsible for the
N-terminal trimming of cytolysin peptides CylLL and CylLS, after
their export (Booth et al., 1996). In this study, LicPwasalso shown
to be a protease involved exclusively in Blib maturation, by
excising the N-terminal hexapeptide from NDVNPE-Blib. More-
over, LicP was present in the supernatants of an E. coli strain
expressing exclusively this protease. The analogous function in
Halb peptide maturation was previously proved in vitro in studies
performed with an undetermined protease present in superna-
tants of B. halodurans C-125 (Cooper et al., 2008). The detection
of Blib peptide in LicDT isopropanol cell washes, albeit in
extremely low amounts, suggests that LicP proteolysis can also
occur in the presence of the full leader sequence.
The LicX sequence is similar to other uncharacterized hypo-
thetical proteins of the Bacillus genus and no conserved motifs
could be identified, making it difficult to predict its function.
Yet, we could establish that LicX is not involved in the Blia and
Blib biosynthesis or its function could be complemented when
using E. coli as the heterologous host. LicR is a predicted
DNA-binding protein with high similarity (60%) to other transcrip-
tional regulators from Bacillus genus. The licR gene inactivation
proved the exclusive involvement of LicR in Blia production,
most probably through the induction of licA1 transcription.
Likewise, disruption of a similar gene,mrsR1 present in the mer-
sacidin biosynthetic cluster strongly decreased its prepeptide
transcription rate resulting in the absence of MrsA production
(Guder et al., 2002; Schmitz et al., 2006). Since Blia and MrsA
peptides are highly homologous (Figure 1) and are produced
byBacillus species, it seems possible that their regulation mech-
anisms have evolved from a common ancestor. The LicY protein
has been found essential for production of the Blib peptide, but
not for production of Blia. LicY does not display significant
similarities to other proteins available in databases, making it
impossible to assign a functional role to this protein. Like
CylR1 of the cytolysines (Coburn and Gilmore, 2003) the LicY
secondary structure is predicted to contain three transmem-
brane helices and a function as a membrane-bound protein
seems likely. CylR1 and CylR2 have been described as a two-
component regulatory system, which represses the expression
of cytolysin genes through a quorum-sensing mechanism
(Haas et al., 2002). Nevertheless, it is difficult to apply this model
to the regulation of Blib expression, since it was not possible to
identify a gene encoding DNA-binding protein within the lic
biosynthetic cluster, which could be associated with Blib
production. In this study, we assigned for the first time to our
knowledge the association of two putative distinct regulatory
elements to the production of one specific single peptide, Blia
or Blib, of the lichenicidin two-component system. We hypothe-
size, that analogousmechanisms of regulation are involved in the
biosynthesis of other two-component lantibiotics, e.g., of halo-
duracin. In fact, the proteins BH0460 and BH0459 encoded
downstream of hal biosynthetic gene cluster show high
homology to LicR (60%) and LicY (61%), respectively. Further
studies examining gene cluster transcription and protein interac-
tion will shed light on the assignment of the exact role of LicR and
LicY on lichenicidin production.
The successful heterologous expression of the lic gene cluster
in E. coli facilitated the establishment of a system for the0–100, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 97
Chemistry & Biology
Heterologous Expression of Lantibiotics in E. coliexpression of lichenicidin variants. The peptides resulting from
Ala substitutions and subsequent MS/MS analysis (of the wild-
type ormutated peptides) allowed the revision of some structural
features of both Blia and Blib previously proposed by (Begley
et al., 2009). Compared with the structurally related two-compo-
nent lantibiotics haloduracin and lacticin, the high number of
serines and threonines in lichenicidin propeptide sequences,
particularly at the N termini, made a clear assignment of dehy-
drated residues difficult. The Ala-scan performed for all Ser-
and Thr-containing positions confirmed that Ser30 escapes
dehydration in Blia and likewise, Thr10, Ser21, and Ser30 remain
unmodified in the Blib peptide. Herein, it was established that
LicM2 dehydrates Thr26 of Blib, similarly to the homologous
residue in Halb (Dhb18), but in contrast to Lctb (Thr23). The exact
molecular masses obtained for Blia and Blib exceed those of
previously determined peptides by +1 Da, indicating that after
proteolysis, a spontaneous deamination of Dhb1 to Obu1 occurs
in both Blia and Blib, as described for Pep5 and Lctb peptides
(Ryan et al., 1999). This is clearly supported by mass spectrom-
etry of peptides BliaT1A and BlibT1A suggesting that Thr1 of
both peptides is not involved in A-ring formation. The fragmenta-
tion pattern of lichenicidin wild-type peptides (Figure 6) rather
indicates that thioether rings are formed between Ser5 or Thr6
with Cys7 (Blia) and Ser7 or Ser8 with Cys11 (Blib). MS/MS
spectra of BliaS5A and BliaT6A, identified Blia Ser5 as the amino
acid involved in the Blia A-ring formation. For Blib the bioactivity
of BlibS7A suggests that Ser7 is the residue for Lan formation
with Cys11. Recently, the structure of lichenicidin peptides
Lcha and Lchb isolated from B. licheniformis VK21 were eluci-
dated by NMR (Shenkarev et al., 2010). In general, the proposed
structures are in agreement with the present work except for the
A-ring of Blia peptide. The MS/MS spectra obtained for Blia of
both B. licheniformis I89, B. licheniformis DSM13 and E. coli
BLic5 exclude the occurrence of a thioether ring between Thr3
and Cys7 due to the presence of an a3-ion. Therefore, Blia and
Lcha may represent natural variants of lanthionine formation.
Yet there is no experimental evidence that minor differences in
dehydratase-cyclase could generate a structural variability,
however, cluster alignment of LicM1 from B. licheniformis I89
(HQ290360) and B. licheniformis VK21 showed the presence of
a 6 aa difference between both modifying enzymes (Figure S5).
Overall, 28 new lichenicidin variants were generated and ex-
pressed inE.coli, showing that the transcomplementationsystem
canbe useful to generate other lichenicidin variants. As expected,
bioactivity but also production was generally affected negatively
when Lan or MeLan rings particularly located at the C-terminal
were disturbed. These results are in accordancewith those of lac-
ticin 3147 in vivo SAR studies (Cotter et al., 2006). Moreover, the
pattern of lanthionine rings (especially B, C, and D rings) seems
to be conserved among two-component lantibiotics, indicating
their importance for the biological activity of these compounds.
This study showed that Gram-negative hosts are able to
synthesize fully bioactive lantibiotics. Based on this system,
amenable and time-saving procedures were developed to inves-
tigate the influence of lic-encoded proteins in the lichenicidin
biosynthesis pathway and to produce new variants of
lantibiotic peptides. Thereby, the present study initiates a new
era in lantibiotics biosynthesis and bioengineering research
employing Gram-negative hosts.98 Chemistry & Biology 18, 90–100, January 28, 2011 ª2011 ElsevierSIGNIFICANCE
This is the first report, to our knowledge, of a lantibiotic
biosynthesis pathway totally reconstituted in vivo in the
heterologous host E. coli, using a vector containing the
whole lichenicidin biosynthetic gene cluster. This system
was used to generate knockout mutants for all the genes
of the lichenicidin biosynthetic gene cluster, except for
ORFs involved in lichenicidin immunity. The following
conclusions could be drawn: (1) LicP is a protease most
probably responsible for the Blib trimming, which activity
seems to be independent of the LicT action; (2) LicX is not
essential for lichenicidin production; and (3) LicR and LicY
are involved exclusively in Blia and Blib biosynthesis.
Furthermore, an in vivo trans complementation system
was developed which allowed production of lichenicidin
peptides with a variety of amino acid substitutions. This
study opens up the possibility for more complex yet time
efficient structure-activity relationship studies on lichenici-
din and may initiate new research efforts in lantibiotic
biosynthesis investigation and bioengineering using Gram-
negative hosts.
EXPERIMENTAL PROCEDURES
The bacterial strains, plasmids, general growth conditions, general reagents
used in molecular biology procedures and antibacterial assays are fully
described in Supplemental Experimental Procedures.
Lichenicidin Heterologous Expression in E. coli
The description of the fosmid library construction is present in the supple-
mental information. E. coli clones positive for lic structural genes were
screened for lichenicidin production by colony bioassay. The production
stability without selective pressure was assessed through sequential subcul-
tures of E. coli clones tested against the indicator strain. Based on these
assays and sequencing, clone Lic5 was selected and its lichenicidin produc-
tion evaluation was performed in medium M, as follows: 1 ml samples were
taken every 2 hr, along 36 hr, from 50 ml cultures and centrifuged for 5 min
at 16,100 3 g. The cell-free supernatant was stored at 20C while cells
were resuspended in 100 ml of 70% isopropanol containing 0.1% of formic
acid. After 2 hr at 4C, cells were centrifuged for 5 min at 16,100 3 g and
the supernatant stored at 20C. Forty microliters of each of the samples
was used for bioassays. Samples exhibiting the major inhibition zone were
selected for LC-ESI-MS analysis. Negative controls consisting of E. coli
EPI300 possessing the empty pCC2FOS vector were also included in this
analysis.
Lichenicidin Gene Cluster Knockout Mutants
In-frame gene deletions of lichenicidin biosynthetic cluster were performed
using the l-Red-mediated recombination system adapted from (Gust et al.,
2003). In brief, the fosmid pLic5 was used to transform electrocompetent
BW25113 cells containing the pKD20 plasmid (BW25113/pKD20/pLic5).
Disruption cassettes for each gene were amplified using as DNA template
the 1383 bp fragment resulting from the digestion of pIJ733 (ApraR) with
EcoRI/HindIII. All the designed primers possess two BmtI restriction sites at
each side of the ApraR cassette (Table S4). At least 100 ng of PCR product
were used to transform electrocompetent BW25113/pKD20/pLic5 cells. Posi-
tive clones were screened by PCR using the respective check primers (Table
S4). Fosmids containing the desired Apra cassette inserted were extracted
from 50 ml overnight cultures using the alkaline lysis procedure (Sambrook
and Russell, 2001) and digested with BmtI (New England Bioloabs) for 3 hr.
Restriction enzyme was removed by phenol/CIA extraction, followed by
DNA precipitation with 1/10 volumes of KAc and 0.6 volumes of isopropanol.
BmtI-digested fosmid was religated in a 50 ml reaction during 15 min at 20CLtd All rights reserved
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competent EPI300 cells. Positive clones were screened by colony-PCR and
tested for the CmR and ApraS phenotype.
LicP Proteolysis Analysis
General procedures involved in the analysis of LicP proteolysis are described
in Supplemental Experimental Procedures.
trans Complementation System
The licA1 and licA2 coding regions were amplified with the primers described
in the primers described in Table S4. PCR products and pET24-a(+) vector
were digested with BamHI and XhoI. After restriction enzymes removal,
licA1 and licA2 digests were ligated to pET24-a(+) to form the plicA1 and
plicA2 plasmids. Five microliters of the ligation reaction was used to transform
chemically competent DH5a cells. Positive clones were screenedwith T7prom
and T7terminator primers and corresponding plasmids extracted with the
GeneJET Plasmid Miniprep Kit (Fermentas). Fifty nanograms of plicA1 and
plicA2 was used to transform chemically competent BLic5DA1 and BLic5DA2
cells, respectively. CloR and KanR clones were confirmed to be positive by
PCR. The restoration of lichenicidin antibiotic activity was assessed by colony
bioassay against M. luteus. Lichenicidin peptides production was confirmed
by LC-ESI-MS analysis of cell and supernatant extracts.
Production of Lichenicidin Variants
Alanine scanning of Blia and Blib peptides was performed by site-directed
mutagenesis of licA1 and licA2 genes, using a modification of the two-step
reactions method described by (Wang and Malcolm, 1999), using plicA1
and plicA2 as templates. Primers used to insert the desired mutation were
designed in the web-based program PrimerX. 5 cycles of amplification were
used in the first PCR and 20 cycles in the second. The parental methylated
DNA was digested with 10 U of DpnI, followed by transformation in DH5a.
Three different KanR clones were selected for plasmid extraction. The insertion
of the desiredmutation in each plasmid was confirmed by sequencing reaction
using T7prom and T7term primers. Finally, mutated plicA1 and plicA2 plas-
mids were transformed in chemically competent BLic5DA1 and BLic5DA2
cells, respectively. Production of Blia and Blib variants was confirmed by
LC-ESI-MS analysis of total extracts (cell and supernatant) and the same
samples were used for antibacterial activity assays.
Preparation of Lichenicidin Extracts for Analysis
For lichenicidin production evaluation, 50 ml cultures in medium M were
performed at 37C with aeration during 24 hr. The cells were pellet by centri-
fugation at 13,0003 g for 5 min, dissolved in 2ml of 70% isopropanol contain-
ing 0.1% formic acid and stored at 4Cduring 3 hr. The cell wall washes extract
was recovered by centrifugation at 13,000 3 g for 5 min and stored at 20C.
2:10 volumes of 1-butanol was added to the cell-free supernatant , and the
mixture was stirred for 1 hr at room temperature and finally centrifuged at
3000 3 g for 1 min. Supernatant extracts corresponding to the upper organic
phase were collected and stored at 20C. For alanine-scan mutants, total
extracts were analyzed. These were obtained by addition of 1:4 volumes of
1-butanol to 20 ml of bacterial culture and sonicated for 15 min. After 1 hr of
stirring, the culture was centrifuged at 4000 3 g for 5 min and the organic
phase was collected. The solvent was evaporated and pellets diluted in 70%
ACN/dH2O.
Mass Spectrometry Analysis
Routine analytics was performed on a qTof 2 hybrid quadrupol time of flight
ESI mass spectrometer (Micromass/Waters, Milford, MA) coupled to an
Agilent 1100 HPLC system (Agilent, Waldbronn, Germany). HR-ESI-MS exper-
iments were obtained on anOrbitrap XLmassspectrometer (Thermo Scientific,
Bremen, Germany) coupled to an Agilent 1200 HPLC system (Agilent Technol-
ogies, Waldbronn, Germany). Separations were performed using a column
Eclipse XDB C-18, 5 mm, 4.6*150 mm (Agilent) with a linear solvent gradient
(5% methanol (0.1% HFo) to 100% methanol (0.1% HFo) in 25 min staying
10 min at 100% organic solvent). MS/MS experiments were performed on
an Agilent triple quadrupole Massspectrometer 6460 coupled with an Agilent
1290 HPLC, equipped with Agilent thermostatted column compartment SL+,
autosampler and binary pump. The injection of pure compounds wasChemistry & Biology 18, 9accomplished via loop injection. For extracts, an Agilent column Eclipse plus
C18 RRHD 1.8 mm, 2.1 3 50 mm was used for separations (gradient from
5% acetonitril to 100% acetonitril in 6 min staying 2 min at 100% acetonitril).
Fragment voltage and collision energy was optimized by each sample.ACCESSION NUMBERS
Coordinates have been deposited in the GenBank database with accession
numbers HQ290359 and HQ290360.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
doi:10.1016/j.chembiol.2010.11.010.
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